Global PET/CT Imaging System Market Strategic Research Report
By Type: New, Refurbished
By Application: Oncology, Cardiology, Neurology, Others
Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America
Key Players: GE HealthCare, Siemens Healthineers, Philips, Canon, Mediso, Neusoft, Positrigo, Positron, Shanghai United Imaging Healthcare, Minfound Medical Systems
Visão geral
Scope of the Report
The global PET/CT Imaging System market size is predicted to grow from US$ 1,321 million in 2025 to US$ 2,318 million in 2032; it is expected to grow at a CAGR of 8.4% from 2026 to 2032.
In 2025, global PET/CT Imaging System capacity 1,000 Units, sales reached approximately 900 Units, with an average market price of around 1,500 k USD/Unit, industrial gross margin 45%.
The PET/CT Imaging System market has moved beyond being a niche nuclear-medicine capital category and is now a core platform for oncology, neurology, cardiology, and theranostics-driven care pathways. The competitive structure is relatively clear: GE HealthCare, Siemens Healthineers, Philips, and United Imaging form the principal global group across digital PET/CT, long-axial-field-of-view PET/CT, total-body PET/CT, and PET/MR. Canon Medical retains relevance in digital PET/CT, mobile deployment, and radiation-oncology-oriented workflow, while Mediso plays a differentiated role in single-room SPECT/CT/PET integration and specialty or research settings. For professional buyers, the key question is no longer whether a PET Imaging System is available, but whether it can support higher throughput, lower dose, stronger quantification, and tighter linkage with radiopharmaceutical and clinical workflow ecosystems.
Competitive differentiation in a PET Imaging System is now defined by a composite performance stack rather than one headline specification. The most decision-relevant parameters are detector architecture, timing resolution and TOF capability, axial field of view, system sensitivity, and the strength of reconstruction and quantification software. The technical trajectory is clear: the market has migrated from earlier BGO and conventional photomultiplier approaches toward LSO/LYSO-based detectors, SiPM and DPC architectures, and wider axial coverage. Public product references illustrate the shift well: Philips Vereos specifies 310 ps timing resolution, GE Omni Legend uses an all-digital platform with a 32 cm axial field of view, Siemens Biograph Vision Quadra extends axial PET coverage to 106 cm, and United Imaging’s uEXPLORER reaches 194 cm for single-bed total-body imaging. In practice, this means procurement is increasingly centered on how many high-quality studies a PET Imaging System can deliver per unit time, how far dose can be reduced, and how effectively the system supports dynamic or multi-organ imaging.
The value chain around a PET Imaging System is broader than that of most conventional imaging modalities. Downstream demand is still anchored in oncology, but neurology, cardiology, therapy planning, response monitoring, and theranostics are lifting utilization and broadening the clinical role of PET. Midstream value lies with system manufacturers, reconstruction software, reading platforms, and service networks. Upstream, the stack includes LSO/LYSO crystals, SiPM/DPC detector assemblies, CT subsystems, high-performance computing, and room-shielding infrastructure. More importantly, PET Imaging Systems are tightly coupled to radiopharmaceutical supply: cyclotrons, hot cells, dispensing, short half-life logistics, and site reliability have a direct effect on scanner economics. Recent moves reinforce that integration. Siemens Healthineers has folded PETNET and AdAcAp under its Radiopharma segment, Curium acquired Nucleis to expand PET manufacturing and distribution in Western Europe, and IBA continues to position cyclotron infrastructure as a core enabler for PET production. The competitive frame is therefore shifting from “selling scanners” to “owning workflow, tracer access, and service continuity.”
The most important recent developments in the PET Imaging System market have centered on long axial field of view, total-body capability, and ecosystem integration. GE HealthCare received CE Mark in November 2025 for the Omni 128 cm total-body PET/CT, pushing the market further toward single-bed head-to-thigh imaging and low-dose workflows. In January 2026, Siemens Healthineers received FDA clearance for the second-generation Biograph One PET/MR, a reminder that PET/MR remains strategically relevant in selected high-end clinical and theranostic contexts. During 2025, Siemens also consolidated its radiopharma branding, while Curium expanded its PET manufacturing footprint through the acquisition of Nucleis. On the commercial side, a particularly useful transaction signal came from The Christie in the UK, which awarded a total-body/long-axial-FoV PET-CT contract to United Imaging in 2025 at about £6.5 million. That kind of procurement decision shows that PET Imaging Systems are increasingly being evaluated not simply as scanners, but as core infrastructure for oncology capacity, referral strategy, and translational research.
Looking ahead, the market path for PET Imaging Systems is unlikely to be defined by simple replacement cycles. Three forces matter most. First, long-axial and total-body PET/CT will continue to move from research-heavy centers into premium clinical practice because higher sensitivity translates into shorter scan times, lower dose, dynamic multi-organ imaging, and better fit for vulnerable populations such as pediatric patients. Second, expansion in radiopharmaceutical use—especially in oncology theranostics and cardiac PET—should increase study frequency and deepen the scanner’s role in multidisciplinary care. Third, AI-based reconstruction, gating, quantification, and compact or mobile deployment models are making PET Imaging Systems more operationally scalable. The most durable growth opportunities therefore sit not only in new placements, but in throughput expansion, dose efficiency, tracer-linked workflows, and the conversion of PET into a more programmable clinical platform.
Key Questions Addressed in this Report
What is the 10-year outlook for the global PET/CT Imaging System market?
What factors are driving PET/CT Imaging System market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PET/CT Imaging System market opportunities vary by end market size?
How does PET/CT Imaging System break out by Type, by Application?
This report presents a comprehensive overview of the global PET/CT Imaging System market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.
Segment by Type
- New
- Refurbished
Segment by Technology
- Conventional Type
- Digital Type
Segment by Axial Field of View
- Standard-AFOV
- Long-AFOV
Segment by Application
- Oncology
- Cardiology
- Neurology
- Others
Who Can Use This Report?
This report is written for decision-makers who need a clear, data-backed view of the global PET/CT Imaging System market:
- Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
- Distributors, channel partners and end users in Oncology, Cardiology, Neurology evaluating demand and sourcing options
- Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
- Government agencies, industry associations and research institutions tracking industry developments and policy impact
Market snapshot
Global PET/CT Imaging System Market Strategic Research Report snapshot, 2025–2032
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.Segments covered in this report
Table of contents
01Executive Summary
02Industry Overview & Forecast
- 2.1.1 Market Definition and Scope
- 2.1.2 Market Size and Growth Forecast
- 2.1.3 Volume Analysis
- 2.1.4 Segment Outlook by Type
- 2.1.5 Segment Outlook by Application
- 2.1.6 Regional Outlook
- 2.1.7 Structural Developments Shaping the Forecast
- 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
- 3.1 Market Segmentation by Type
- 3.1.1 Market by Type Overview
- 3.1.2 New
- 3.1.3 Refurbished
- 3.1.4 Volume Analysis
04Market Segmentation by Application
- 4.1 Market Segmentation by Application
- 4.1.1 Market by Application Overview
- 4.1.2 Oncology
- 4.1.3 Cardiology
- 4.1.4 Neurology
- 4.1.5 Others
- 4.1.6 Volume Analysis
05Regional Market Forecast
- Asia Pacific
- North America
- Europe
- Middle East & Africa
- Latin America
06Country-Level Market Forecast
- 6.1 Asia Pacific
- 6.1.1 China
- 6.1.2 Japan
- 6.1.3 Korea
- 6.1.4 Southeast Asia
- 6.1.5 India
- 6.1.6 Australia
- 6.1.7 Rest of Asia Pacific
- 6.2 North America
- 6.2.1 United States
- 6.2.2 Canada
- 6.2.3 Mexico
- 6.2.4 Rest of North America
- 6.3 Europe
- 6.3.1 Germany
- 6.3.2 France
- 6.3.3 UK
- 6.3.4 Italy
- 6.3.5 Russia
- 6.3.6 Rest of Europe
- 6.4 Middle East & Africa
- 6.4.1 Egypt
- 6.4.2 South Africa
- 6.4.3 Israel
- 6.4.4 Turkey
- 6.4.5 GCC Countries
- 6.4.6 Rest of Middle East & Africa
- 6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
- 7.1 Growth Drivers & Inhibitors
- 7.1.1 Section Overview
- 7.1.2 Growth Drivers
- 7.1.3 Growth Inhibitors
- 7.1.4 Driver and Inhibitor Impact Assessment
- 7.1.5 Analyst Perspective
08Key Company Profiles
- 8.1 GE HealthCare
- 8.1.1 Company Overview
- 8.1.2 Key Products & Segments
- 8.1.3 Financial Performance (2023–2025)
- 8.1.4 Business Strategy
- 8.1.5 SWOT Analysis
- 8.1.6 Strategic Implications (2026–2032)
- 8.2 Siemens Healthineers
- 8.2.1 Company Overview
- 8.2.2 Key Products & Segments
- 8.2.3 Financial Performance (2023–2025)
- 8.2.4 Business Strategy
- 8.2.5 SWOT Analysis
- 8.2.6 Strategic Implications (2026–2032)
- 8.3 Philips
- 8.3.1 Company Overview
- 8.3.2 Key Products & Segments
- 8.3.3 Financial Performance (2023–2025)
- 8.3.4 Business Strategy
- 8.3.5 SWOT Analysis
- 8.3.6 Strategic Implications (2026–2032)
- 8.4 Canon
- 8.4.1 Company Overview
- 8.4.2 Key Products & Segments
- 8.4.3 Financial Performance (2023–2025)
- 8.4.4 Business Strategy
- 8.4.5 SWOT Analysis
- 8.4.6 Strategic Implications (2026–2032)
- 8.5 Mediso
- 8.5.1 Company Overview
- 8.5.2 Key Products & Segments
- 8.5.3 Financial Performance (2023–2025)
- 8.5.4 Business Strategy
- 8.5.5 SWOT Analysis
- 8.5.6 Strategic Implications (2026–2032)
- 8.6 Neusoft
- 8.6.1 Company Overview
- 8.6.2 Key Products & Segments
- 8.6.3 Financial Performance (2023–2025)
- 8.6.4 Business Strategy
- 8.6.5 SWOT Analysis
- 8.6.6 Strategic Implications (2026–2032)
- 8.7 Positrigo
- 8.7.1 Company Overview
- 8.7.2 Key Products & Segments
- 8.7.3 Financial Performance (2023–2025)
- 8.7.4 Business Strategy
- 8.7.5 SWOT Analysis
- 8.7.6 Strategic Implications (2026–2032)
- 8.8 Positron
- 8.8.1 Company Overview
- 8.8.2 Key Products & Segments
- 8.8.3 Financial Performance (2023–2025)
- 8.8.4 Business Strategy
- 8.8.5 SWOT Analysis
- 8.8.6 Strategic Implications (2026–2032)
- 8.9 Shanghai United Imaging Healthcare
- 8.9.1 Company Overview
- 8.9.2 Key Products & Segments
- 8.9.3 Financial Performance (2023–2025)
- 8.9.4 Business Strategy
- 8.9.5 SWOT Analysis
- 8.9.6 Strategic Implications (2026–2032)
- 8.10 Minfound Medical Systems
- 8.10.1 Company Overview
- 8.10.2 Key Products & Segments
- 8.10.3 Financial Performance (2023–2025)
- 8.10.4 Business Strategy
- 8.10.5 SWOT Analysis
- 8.10.6 Strategic Implications (2026–2032)
09Competitive Landscape
- 9.1 Competitive Landscape Overview
- 9.2 Competitive Intensity Assessment
- 9.3 Key Player Strategies & Positioning
- 9.4 Competitive Dynamics & Strategic Outlook
- 9.4.1 Emerging Competitive Threats
- 9.4.2 Consolidation vs. Fragmentation Outlook
- 9.4.3 Competitive Response Matrix
- 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
- 10.1 Threat of New Entrants
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Threat of Substitutes
- 10.5 Competitive Rivalry
11PESTLE Analysis
- 11.1 Political
- 11.2 Economic
- 11.3 Social and Demographic
- 11.4 Technological
- 11.5 Legal and Regulatory
- 11.6 Environmental
- 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
- 13.1 Future Trends & Outlook
- 13.1.1 Trend Summary and Commercial Maturity Assessment
- 13.1.2 Technology and Innovation Trends
- 13.1.3 Long-Term Market Outlook
- 13.1.4 Investment & M&A Activity Outlook
- 13.1.5 Overall Outlook Assessment
Frequently asked questions
How big is the global PET/CT Imaging System market?
How fast is the PET/CT Imaging System market expected to grow?
What does the PET/CT Imaging System market cover?
How is the PET/CT Imaging System market segmented by type?
What are the key applications of PET/CT Imaging System?
Which companies are profiled in the PET/CT Imaging System market report?
What geographies does the PET/CT Imaging System market analysis include?
What are the key demand drivers for PET/CT Imaging System?
Who should buy the PET/CT Imaging System market report?
What license options are available for this report?
Research Methodology
All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.
Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.
Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.
Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.
CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.
All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.
On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.
Need a customized version?
Get country-, segment- or company-specific intelligence tailored to your exact requirements.
Request custom research →Request a free sample
Receive a sample of Global PET/CT Imaging System Market Strategic Research Report before you buy.
Customize This Report
Describe your specific requirements and our analysts will scope and deliver a tailored version.
Request Invoice
We will email a proforma invoice within 24 hours. Report access is granted upon payment confirmation.
Navadhi Market Research · Consumer Goods & Retail